Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
Meletios Dimopoulos: Weekly SVd Improved PFS in Relapsed/Refractory Myeloma
Once weekly combination treatment with selinexor, bortezomib, and dexamethasone led to an approximately 4-month improvement in progression-free survival compared with bortezomib plus dexamethasone. Meletios...
Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma
Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...
DVT Increases Health-Care Burden and Mortality in Patients with Cancer
Patients with cancer and deep vein thrombosis (DVT) experience higher rates of hospitalization and mortality, are less frequently treated with thrombolysis, and experience gastrointestinal...
DREAMM-6: Evaluating Belantamab Mafodotin and Bortezomib Plus Dexamethasone in Relapsed/Refractory Myeloma
Early data from the DREAMM-6 study suggest that the combination of belantamab mafodotin, bortezomib, and dexamethasone is active in patients with relapsed or refractory...
BOSTON: Weekly Combination Therapy Including Selinexor Improved PFS in Relapsed/Refractory Myeloma
Once weekly combination treatment with selinexor, bortezomib, and dexamethasone (SVd) led to an approximately 4-month improvement in progression-free survival (PFS) compared with bortezomib plus...
Current Issue
June 2020, Volume 6, Issue 7
This issue explores COVID-19-associated coagulopathy, features frequently asked questions from oncologists, and more.
